Fort Washington Investment Advisors Inc. OH Cuts Stock Position in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)

Fort Washington Investment Advisors Inc. OH trimmed its position in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) by 1.7% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 715,500 shares of the biotechnology company’s stock after selling 12,170 shares during the period. Fort Washington Investment Advisors Inc. OH owned approximately 0.38% of BioMarin Pharmaceutical worth $47,030,000 as of its most recent SEC filing.

Several other institutional investors also recently bought and sold shares of the company. Susquehanna Fundamental Investments LLC purchased a new stake in shares of BioMarin Pharmaceutical in the second quarter valued at about $5,627,000. Teachers Retirement System of The State of Kentucky raised its holdings in BioMarin Pharmaceutical by 17.4% during the second quarter. Teachers Retirement System of The State of Kentucky now owns 194,207 shares of the biotechnology company’s stock worth $15,990,000 after purchasing an additional 28,837 shares in the last quarter. Assenagon Asset Management S.A. lifted its position in BioMarin Pharmaceutical by 461.3% in the fourth quarter. Assenagon Asset Management S.A. now owns 611,667 shares of the biotechnology company’s stock valued at $40,205,000 after purchasing an additional 502,695 shares during the period. Wedmont Private Capital purchased a new stake in BioMarin Pharmaceutical in the 4th quarter valued at approximately $430,000. Finally, EULAV Asset Management increased its position in BioMarin Pharmaceutical by 12.9% during the 3rd quarter. EULAV Asset Management now owns 131,000 shares of the biotechnology company’s stock worth $9,208,000 after purchasing an additional 15,000 shares during the period. 98.71% of the stock is owned by institutional investors and hedge funds.

BioMarin Pharmaceutical Price Performance

NASDAQ:BMRN opened at $62.53 on Wednesday. The firm has a market cap of $11.92 billion, a price-to-earnings ratio of 37.44, a price-to-earnings-growth ratio of 0.54 and a beta of 0.29. BioMarin Pharmaceutical Inc. has a 12-month low of $60.63 and a 12-month high of $94.85. The company has a current ratio of 4.27, a quick ratio of 2.62 and a debt-to-equity ratio of 0.11. The company’s 50-day moving average is $65.39 and its two-hundred day moving average is $74.15.

BioMarin Pharmaceutical (NASDAQ:BMRN) last announced its earnings results on Tuesday, October 29th. The biotechnology company reported $0.55 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.78 by ($0.23). The firm had revenue of $746.00 million for the quarter, compared to analyst estimates of $703.37 million. BioMarin Pharmaceutical had a return on equity of 8.53% and a net margin of 11.71%. The firm’s revenue was up 28.4% compared to the same quarter last year. During the same quarter last year, the business posted $0.26 EPS. Research analysts expect that BioMarin Pharmaceutical Inc. will post 2.5 EPS for the current year.

Insider Activity

In other BioMarin Pharmaceutical news, EVP Charles Greg Guyer sold 5,278 shares of the firm’s stock in a transaction dated Tuesday, November 12th. The stock was sold at an average price of $66.37, for a total value of $350,300.86. Following the sale, the executive vice president now directly owns 68,909 shares of the company’s stock, valued at approximately $4,573,490.33. This trade represents a 7.11 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 1.85% of the company’s stock.

Analysts Set New Price Targets

Several analysts have recently commented on the company. Raymond James reissued an “outperform” rating and issued a $79.00 price target on shares of BioMarin Pharmaceutical in a report on Thursday, October 10th. JPMorgan Chase & Co. reduced their target price on BioMarin Pharmaceutical from $110.00 to $109.00 and set an “overweight” rating for the company in a report on Wednesday, October 30th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $90.00 price target on shares of BioMarin Pharmaceutical in a research note on Thursday, December 12th. Royal Bank of Canada reiterated a “sector perform” rating and issued a $80.00 price target on shares of BioMarin Pharmaceutical in a report on Wednesday, October 30th. Finally, Barclays decreased their price objective on shares of BioMarin Pharmaceutical from $110.00 to $86.00 and set an “overweight” rating on the stock in a report on Friday, October 4th. Seven analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $94.20.

BioMarin Pharmaceutical Company Profile

BioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.